恭喜PGDx获肿瘤免疫领导企业BMS投资
原标题：恭喜PGDx获肿瘤免疫领导企业BMS投资，凯风基金在主导天使轮后于A、B轮持续跟进！
PGDx致力于将复杂的癌症测序诊断产品标准化，获得FDA批准后为全世界实验室所用，PGDx继A轮获得美国最大的生物医疗技术投资基金NEA（恩颐投资）投资后又在B轮获得肿瘤免疫领导企业BMS（百时美施贵宝制药）投资，凯风创投始终用全球化的眼光对处于发展前沿的生物医药技术持续深入关注。在主导了天使轮投资的基础上在A轮和B轮持续跟进。
PGDx has rolled out a range of cancer tests since being founded by researchers at Johns Hopkins University in 2010. The portfolio includes tests designed to detect genetic mutations relevant to the treatment of multiple cancer types in tissue, blood or plasma samples. PDGx now wants to secure regulatory clearances for its tissue and liquid biopsies and equip local laboratories to run the tests.
NEA, which led PDGx’s $21 million series A round in 2015, has joined with Bristol-Myers to help make this happen. The co-leads of the series B were joined in the round by a mix of new and existing backers including Inova Strategic Investments, Co-win Healthcare Fund and Helsinn Investment Fund.
The involvement of Bristol-Myers builds on work PGDx has carried out for the Big Pharma, which was one of its early customers. PGDx has landed contracts with Bristol-Myers and other drug developers on the strength of its ability to sequence samples and algorithmically analyze the resulting data to glean insights into tumor genetics and treatment options.
RELATED: NEA backs cancer genome Dx startup Personal Genome in $21M+ series A
PDGx is equipped to process, sequence and analyze DNA, frozen tissue, liquid biopsies and other samples. But its plan is to globalize and decentralize testing by making regulated IVDs available to laboratories around the world.
“We believe that tailoring therapies to [key genomic drivers of clinical response] is best accomplished by making testing be run by local laboratories,” PGDx CEO Douglas Ward said in a statement.
PDGx will work toward this goal while expanding its own infrastructure. The Baltimore, Maryland-based company is expanding into a facility close to its current base to triple its overall space. PDGx will fill the additional space with multiple laboratories and workspaces.
PGDx致力于将复杂的癌症测序诊断产品标准化，获得FDA批准后为全世界实验室所用，PGDx继A轮获得美国最大的生物医疗技术投资基金NEA（恩颐投资）投资后又在B轮获得肿瘤免疫领导企业BMS（百时美施贵宝制药）投资，凯风创投始终用全球化的眼光对处于发展前沿的生物医药技术持续深入关注。在主导了天使轮投资的基础上在A轮和B轮持续跟进。
PGDx has rolled out a range of cancer tests since being founded by researchers at Johns Hopkins University in 2010. The portfolio includes tests designed to detect genetic mutations relevant to the treatment of multiple cancer types in tissue, blood or plasma samples. PDGx now wants to secure regulatory clearances for its tissue and liquid biopsies and equip local laboratories to run the tests.
NEA, which led PDGx’s $21 million series A round in 2015, has joined with Bristol-Myers to help make this happen. The co-leads of the series B were joined in the round by a mix of new and existing backers including Inova Strategic Investments, Co-win Healthcare Fund and Helsinn Investment Fund.
The involvement of Bristol-Myers builds on work PGDx has carried out for the Big Pharma, which was one of its early customers. PGDx has landed contracts with Bristol-Myers and other drug developers on the strength of its ability to sequence samples and algorithmically analyze the resulting data to glean insights into tumor genetics and treatment options.
The involvement of Bristol-Myers builds on work PGDx has carried out for the Big Pharma.
RELATED: NEA backs cancer genome Dx startup Personal Genome in $21M+ series A
PDGx is equipped to process, sequence and analyze DNA, frozen tissue, liquid biopsies and other samples. But its plan is to globalize and decentralize testing by making regulated IVDs available to laboratories around the world.
“We believe that tailoring therapies to [key genomic drivers of clinical response] is best accomplished by making testing be run by local laboratories,” PGDx CEO Douglas Ward said in a statement.
PDGx will work toward this goal while expanding its own infrastructure. The Baltimore, Maryland-based company is expanding into a facility close to its current base to triple its overall space. PDGx will fill the additional space with multiple laboratories and workspaces.